Consensus on the management of patients with psoriatic arthritis in a dermatology setting.

about

Consensus on the management of patients with psoriatic arthritis in a dermatology setting.

Item

http://www.wikidata.org/entity/Q50002313

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Consensus on the management of ...... itis in a dermatology setting.

@en

Consensus on the management of ...... itis in a dermatology setting.

@nl

type

Item

label

Consensus on the management of ...... itis in a dermatology setting.

@en

Consensus on the management of ...... itis in a dermatology setting.

@nl

prefLabel

Consensus on the management of ...... itis in a dermatology setting.

@en

Consensus on the management of ...... itis in a dermatology setting.

@nl

P1476

Consensus on the management of ...... itis in a dermatology setting.

@en

P2093

A Marchesoni

http://www.w3.org/2001/XMLSchema#string

A Parodi

http://www.w3.org/2001/XMLSchema#string

C De Simone

http://www.w3.org/2001/XMLSchema#string

C Foti

http://www.w3.org/2001/XMLSchema#string

C Salvarani

http://www.w3.org/2001/XMLSchema#string

E Lubrano

http://www.w3.org/2001/XMLSchema#string

F Ayala

http://www.w3.org/2001/XMLSchema#string

G Altomare

http://www.w3.org/2001/XMLSchema#string

G Girolomoni

http://www.w3.org/2001/XMLSchema#string

G Malara

http://www.w3.org/2001/XMLSchema#string

P2860

Magnetic resonance imaging in psoriatic arthritis: a review of the literature

Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds En

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Psoriatic Arthritis.

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

Psoriatic arthritis: a unified concept twenty years on.

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas

Validity, reliability, and sensitivity-to-change properties of the psoriatic arthritis screening and evaluation questionnaire.

The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy.

Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study).

P304

515-528

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JDV.14741

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Andrea Conti

Luca Idolazzi

P577

2017-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29220551

http://www.w3.org/2001/XMLSchema#string